Gilead Sciences, Inc. Buyback
OLI recorded this information on 2/3/2015
Company: |
Gilead Sciences, Inc. |
Buyback: |
GILD buyback |
$Amount Authorized: |
$15,000,000,000 |
Buyback Details: |
The Board of Directors also approved the repurchase of up to an additional $15.0 billion of the company's common stock. This new program is in addition to the currently authorized three-year $5.0 billion repurchase program (authorized in May 2014). As of December 31, 2014, approximately $3 billion remained in the May 2014 program. The new program will expire 5 years after the completion of the May 2014 program. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Gilead's management and in accordance with the requirements of the Securities and Exchange Commission. |
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.
Gilead Sciences SEC Filing Email Alerts Service
Open the GILD Page at The Online Investor »
Company Name: |
Gilead Sciences Inc |
Stock buyback: |
GILD buyback |
Website: |
www.gilead.com |
Sector: |
Biotechnology |
Number of ETFs Holding GILD: |
133 |
Total Market Value Held by ETFs: |
$13.37B |
Total Market Capitalization: |
$84.40B |
% of Market Cap. Held by ETFs: |
15.84% |
|
Open the GILD Page at The Online Investor (in a new window) »
|
April 17, 2024 11:50 PM Eastern
Buy (2.83 out of 4)
100th percentile
|
|